Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

PCAS Report Publication Announcement 2021

May 5, 2021

1590_10-k_2021-05-05_0ec87565-4c8a-4cb0-b6e7-8cac59ad362e.pdf

Report Publication Announcement

Open in viewer

Opens in your device viewer

RELEASE OF THE 2020 UNIVERSAL REGISTRATION DOCUMENT (URD)

Ecully, May 5, 2021

The PCAS Universal Registration Document 2020, which includes the annual financial report, was filed with France's Financial Markets Authority on May 5, 2021, under number D.21-0429.

This document contains:

  • The 2020 annual financial report
  • The Board of Directors' corporate governance report in accordance with Section L.225-37 of France's Commercial Code
  • Information on the statutory auditors' fees

This document is now available:

  • At PCAS headquarters: 21 chemin de la Sauvegarde, 21 Ecully Parc, CS 33167, 69134 Ecully, France
  • On the company website: www.pcas.com

NEXT FINANCIAL DISCLOSURE:

2020 Shareholder's Meeting in Ecully at 10 a.m. on June 9, 2021

ABOUT PCAS

PCAS specializes in the development and production of complex molecules for life sciences and innovative technologies. With 10% of its net sales earmarked for R&D and a large international footprint, PCAS is the preferred industrial partner for marketleading major global groups. Boasting especially high standards, the company offers a growing range of proprietary products and solutions in leading-edge segments. PCAS generated net sales of €194.1 million in 2020 and employs close to 1 100 people in six countries.

To find out more about PCAS: www.pcas.com

Tél. : +33 1 69 79 60 00 www.pcas.com

PCAS Newcap

Pierre Luzeau / Eric Moissenot Emmanuel Huynh / Louis-Victor Delouvrier Financial communication and investor relations

Tél. : +33 1 44 71 98 53 [email protected]